​​​giving men a better chance of beating prostate cancer 

​​​​​​​​​​​​​On 29th January 2016, the Prostate Project celebrated 10 years of campaigning which has helped put Surrey at the forefront of the fight against cancer. In 2006 the Prostate Project jointly established and funded a research group with the University of Surrey, led by Professor Hardev Pandha, which has had breakthroughs in cancer immunotherapy, and detecting and treating the disease. We welcomed about 100 supporters to the labs at the University, and Prof Pandha and his team gave a serious of presentations about the research successes to date and the future direction for the team.  

A particular success has been the research into a protein called Engrailed -2 (EN2), which has led to an

urine test being developed to detect prostate cancer.

Prof Pandha said: “The EN2 urine test programme was a result of an ‘eureka moment’ in the laboratories

at Surrey University. One member of the team, Richard Morgan, has a background in studying genes that

direct the normal growth of the embryo through its various stages until birth.  EN2 is a gene that closely

orchestrates the development of the brain and limbs. It is normally ‘switched off’ once a baby is born but

in cancer there is compelling evidence it is switched on again and helps drive cancer growth. In addition,

EN2 has one unique property in that it is a small sticky protein which is made by cancer cells, exported

outside the cell and taken up by other cells”

Prof Pandha said that whilst examining images of prostate cancer, the researchers noticed large deposits

of EN2 accumulating outside cells.

The team then predicted that EN2 could be expressed by these cells and secreted into urine, which a test confirmed.  This led to six years of clinical trials in a number of countries.  These findings overall confirm EN2 is very good at detecting prostate cancer and also may be capable of indicating when patients have small cancers, which could be observed and monitored, versus large cancers which need treatment immediately. Such a test would have very high clinical utility and potentially save patients from invasive surgery and unnecessary treatment.

This has lead to a 500-man clinical trial called
Procure, funded by our OctoBeardFest campaign and Randox Laboratories, which will also study bladder cancers and whether EN2 can predict small tumours. 

The EN2 study has also furthered research into immunotherapy, which uses the body’s own immune system to target tumour cells leaving normal cells untouched.

Dr Nicola Annels, senior scientist and head of the team’s immunotherapy programme, said: “We have several lines of research that aim to understand and overcome the major mechanisms that tumours use to suppress the immune response.  In some cases, tumours are capable of recruiting immune cells that are helpful to the tumour. One of these cell types is called regulatory T cells and they work to reduce the immune response around the tumour.  One of our current lines of research is developing a novel agent to target these regulatory T cells. In preclinical work in the labs we have shown that our agent is able to disrupt the function of these regulatory T cells and leads to enhanced immune responses". For further information about Dr Annels' work, please click here.

Dr Guy Simpson, senior scientist specialising in Oncolytic Viral Therapy explained how the team have been investigating how to use viruses to cure cancer.  Oncolytic (cancer killing) viruses can grow in and kill bladder and prostate cancer cells, leaving the surrounding healthy cells unharmed.  For further information about this research and the world first in- man clinical trial that the team is running, click here.

Over the past seven years, the team have run, through the support of the Prostate Project, the SUN study.  This is a biobank of serum and DNA samples from patients with prostate cancer.  Dr Agnieszka Michael, in charge of the study, said, "The primary purpose of the SUN study was to collect blood samples from men with a diagnosis of prostate cancer and compare these with samples from an age-related group of healthy men to detect new biomarkers and aid in the early detection and monitoring of prostate cancer. Over the next 2-3 years we consented approximately 600 men, of those 314 men had a diagnosis of prostate cancer and 278 were healthy volunteers. The study has an NHS ethics approval, protocol and consent form and                       although the active collection has now stopped the biobank contains serum samples, DNA samples and some urine samples".  Click here for more details.

                                          Colin Stokes, our chairman said “we are so proud of our research team’s achievements.                                                              Their ground-breaking work is giving men a much better chance of beating prostate                                                                  cancer.  That is the premise on which our charity was founded and remains our principal                                                            goal today.  In the last 18 years we have raised £8.4 million and made a significant                                                                    contribution towards the Royal Surrey becoming a centre of excellence.

10 Years Celebration of Cancer Research at the University of Surrey

Key Achievements

  • Development of a unique diagnostic urine test (EN2) for prostate cancer, the first breakthrough since the PSA test 30 years ago.  Two commercial diagnostic companies have taken licenses
  • EN2 has also been identified as a potential immunotherapeutic drug target on cancer cells, allowing the immune system to target just the cancer cells, leaving the healthy cells unharmed
  • Identification and development of HXR9 as a novel targeted cancer drug, which can be injected into the tumour or taken as a tablet treatment. The cancer cells are targeted and causes them to self destruct.  A spin-off company has been established, HOX Therapeutics Ltd, which will continue to study HXR9 and carry out first in-man clinical trials.
  • Development of  a novel peptide agent, HWFT, to enhance cancer vaccine efficacy
  • One of 3 pioneering centres in the UK to use live viruses to treat cancer
  • The group has been instrumental in bringing immune-based treatments to the clinic, initially with cancer vaccines, but now with agents including live viruses which destroy cancer cells and alert the immune system to destroy the cancer
  • Establishment of the SUN study – a bio-repository and accompanying ‘database’ of 450 patients with all stages of prostate cancer.  This allows access and participation in the worldwide consortium, 'PRACTICAL', a study of prostate cancer involving 800,000 men
  • Clinical Trials involving cutting edge new agents
  • 160 publication in peer reviewed journals (including 'Nature') and a new text book ‘Viral Therapy of Cancer’
  • Practice changing discovery that for patients with locoregional renal-cell carcinoma at high risk for tumour recurrence after nephrectomy who received adjuvant treatment with Sunitinib (a targeted cancer treatment) had a longer duration of disease-free survival than did those receiving placebo
  • National and international collaborations - University of California, Cornell Medical School, University of Leeds, Mayo Clinic, Royal Marsden London, and others
  • 5 Patents filed

To find out more about the Oncology research team at the Leggett Building, visit theUniversity of Surrey website.

Copyright ©​  The Prostate Project. All Rights Reserved. Tel 07724465883 info@prostate-project.org.uk  Charity No. 1078523